Loading...
Loading...
Browse all stories on DeepNewz
VisitMerck Acquires CN201 B-Cell Therapy for Up to $1.3 Billion
Aug 9, 2024, 12:11 PM
Merck has announced its acquisition of CN201, an investigational B-cell depletion therapy, from Curon Biopharmaceutical. CN201 is a next-generation CD3xCD19 bispecific antibody that aims to enhance and diversify Merck's pipeline. The drug has potential applications in treating B-cell malignancies and autoimmune diseases. The deal is valued at up to $1.3 billion, reflecting Merck's continued investment in innovative therapies.
View original story
Markets
No • 50%
Yes • 50%
FDA announcements and official Merck press releases
Yes • 50%
No • 50%
FDA announcements and official Merck press releases
No • 50%
Yes • 50%
Stock market data from sources like Yahoo Finance, Nasdaq, or Bloomberg
$500 million to $1 billion • 25%
More than $1 billion • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
Merck's financial statements and earnings reports
Increased marketing for existing drugs • 25%
New competing drug approved • 25%
No significant response • 25%
Price reduction in similar drugs • 25%
Official announcements from competing pharmaceutical companies
Mixed results • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Official trial results published by Merck or clinical trial registries